Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levoleucovorin

FDA-approved product (powder, intravenous), marketed as Khapzory, Fusilev, Levoleucovorin Calcium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Levoleucovorin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Osteosarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Levoleucovorin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levoleucovorin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

    NCT00004228 · start 2000-06

    Registered record
    Registry ID
    NCT00004228
    Conditions
    Lymphoma
    Interventions
    asparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; leucovorin calcium; mercaptopurine; methotrexate; prednisone; thioguanine; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-06
    Completion
    2015-03-31
    Enrolment
    393

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionasparaginase; cyclophosphamide; cytarabine; daunorubicin hydrochloride +9 more
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

    NCT00019513 · start 1998-08

    Registered record
    Registry ID
    NCT00019513
    Conditions
    Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer; Lung Cancer; Lymphoma; Pancreatic Cancer; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    fluorouracil; gemcitabine hydrochloride; leucovorin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1998-08
    Completion
    2004-06
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer +6 more
    Interventionfluorouracil; gemcitabine hydrochloride; leucovorin calcium
    PhasePhase 1
    Registry statusCompleted

  • Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer

    NCT00005979 · start 1998-07-22

    Registered record
    Registry ID
    NCT00005979
    Conditions
    Colorectal Cancer
    Interventions
    FOLFIRI regimen; fluorouracil; irinotecan hydrochloride; leucovorin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-07-22
    Completion
    2007-09-01
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionFOLFIRI regimen; fluorouracil; irinotecan hydrochloride; leucovorin calcium
    PhasePhase 3
    Registry statusCompleted

  • Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma

    NCT00002618 · start 1994-12

    Registered record
    Registry ID
    NCT00002618
    Conditions
    Lymphoma
    Interventions
    filgrastim; cytarabine; doxorubicin hydrochloride; leucovorin calcium; mercaptopurine; methotrexate; prednisone; vincristine sulfate; low-LET cobalt-60 gamma ray therapy; low-LET electron therapy; low-LET photon therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1994-12
    Completion
    2006-09
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; cytarabine; doxorubicin hydrochloride; leucovorin calcium +7 more
    PhasePhase 3
    Registry statusCompleted

  • Dose-Dense Therapy in Aggressive Lymphoma

    NCT00517894

    Registered record
    Registry ID
    NCT00517894
    Conditions
    Lymphoma
    Interventions
    CEOP/IMVP-Dexa chemotherapy
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionCEOP/IMVP-Dexa chemotherapy
    PhaseNot recorded
    Registry statusNo longer available